NanoVibronix logo
NanoVibronix NAOV

Quarterly report 2025-Q3
added 11-14-2025

report update icon

NanoVibronix Financial Ratios 2011-2025 | NAOV

Annual Financial Ratios NanoVibronix

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-0.2 -0.0 -0.9 -0.1 -2419.8 -3.4 -5.2 -4.7 -9.7 -3.3 - - - -

P/S

0.4 0.1 6.4 0.6 16798.7 36.7 67.9 98.0 120.0 64.6 - - - -

EPS

-13.7 -23.3 -3.8 -11.3 -0.4 -0.8 -0.6 -1.2 -0.6 -0.8 -17.1 - - -

EV (Enterprise Value)

3.17 M -462 K 4.76 M -4.4 M 3.33 M 18.8 M 21.8 M 20.3 M 30.4 M 10.1 M 6.25 M 3.99 M 2.18 M 1.67 M

EBITDA per Share

-13.3 -21.6 -3.53 -4.52 -0.000505 -0.742 -0.666 -0.622 -0.504 -0.716 - - - -

EV/EBITDA

1.0 -2217.2 -3.5 -4.8 -6.2 -11.9 -5.6 - - - -

PEG

-0.0 -0.0 -0.0 -0.0 -24.21 0.11 -0.11 0.05 -0.17 0.07 - - - -

P/B

1.5 0.0 1.5 0.2 4371.6 14.4 46.7 6.4 -11.0 -45.4 - - - -

P/CF

-0.4 -0.0 -0.7 -0.2 -3084.5 -5.0 -6.1 -10.7 -17.8 -6.4 - - - -

ROE %

-590.91 -93.05 -168.51 -226.23 -180.66 -429.82 -897.19 -136.63 113.29 1379.90 - - - -

ROA %

-102.09 -55.60 -92.67 -165.65 -52.56 -284.58 -262.91 -102.06 -573.08 -145.44 - - - -

ROCE %

-571.29 -86.16 -155.03 -90.02 -88.59 -316.59 -457.77 -75.98 3261.97 -84.52 - - - -

Current Ratio

1.2 2.5 2.2 3.7 2.7 4.5 1.9 5.7 0.4 6.0 - - - -

DSO

29.7 26.1 50.7 24.2 156.4 89.5 165.3 53.5 22.3 101.8 - - - -

DIO

855.7 1200.4 733.1 63.1 129.4 177.4 332.7 315.2 277.9 528.9 - - - -

DPO

32.2 49.9 47.7 45.6 435.5 189.1 445.9 696.8 340.1 432.0 - - - -

Operating Cycle

885.3 1226.6 783.8 87.4 285.8 266.9 497.9 368.7 300.2 630.7 - - - -

Cash Conversion Cycle

853.2 1176.7 736.1 41.8 -149.7 77.8 52.1 -328.1 -39.9 198.6 - - - -

All numbers in USD currency

Quarterly Financial Ratios NanoVibronix

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.91 -1.03 - - -3.56 -27.18 2.38 - -0.42 -0.65 -0.67 - -0.68 -0.93 -0.81 - -0.26 -0.01 -0.2 - -0.1 -0.2 -0.13 - -0.12 -0.16 -0.4 - -0.21 -0.13 -0.12 - -0.35 -0.18 -0.37 - -0.13 -0.13 -0.11 - -0.82 -0.82 -0.85 - -4.94 -3.73 -3.24 - - - - - - - - - - - -

EBITDA per Share

- - -2.93 - - - - - - - -0.64 - -0.66 -0.91 -0.79 - -0.03 -0.04 -0.05 - -0.09 -0.2 -0.12 - -0.11 -0.13 -0.33 - -0.21 -0.13 -0.12 - -0.13 -0.14 -0.17 - -0.12 -0.1 -0.1 - -0.09 -0.09 -0.42 - -3.3 -1.71 0.89 - - - - - - - - - - - -

ROE %

-68.92 -123.43 -137.83 -94.31 -109.81 -72.00 -139.97 -157.49 -187.76 -202.54 -141.85 -83.29 -159.91 -206.26 -179.95 -194.93 -233.44 -195.33 -251.83 -138.68 -199.14 -221.09 -241.51 -341.32 -631.60 -861.42 -957.27 -638.66 -682.66 -436.38 -281.78 -91.50 -67.25 1.00 48.78 68.47 565.60 1038.48 1221.72 1006.22 1019.86 536.37 339.01 32.89 32.89 19.25 8.96 - - - - - - - - - - - -

ROA %

-33.75 -56.00 -60.37 -42.82 -52.70 -41.26 -57.22 -60.71 -79.04 -87.50 -79.36 -53.00 -122.06 -172.79 -156.05 -129.37 -140.58 -82.72 -97.51 -40.35 -80.37 -109.20 -145.62 -225.98 -311.05 -356.08 -353.86 -187.15 -220.02 -167.82 -133.12 -68.35 -191.02 -280.82 -386.85 -346.36 -398.75 -328.47 -226.88 -106.05 -212.00 -265.55 -323.61 -255.46 -255.46 -149.52 -69.57 - - - - - - - - - - - -

ROCE %

- - - - - - - - -29.30 -58.59 -89.26 -81.10 -91.07 -71.73 -64.86 -63.99 -97.58 -121.19 -158.72 -132.79 -180.39 -194.40 -187.22 -216.80 -305.08 -345.77 -379.39 -260.09 -272.69 -197.01 -125.47 -48.54 719.07 1499.27 2157.75 2077.46 2057.42 1269.76 608.83 -57.18 -46.15 -15.07 9.32 13.67 13.67 2.64 -3.07 - - - - - - - - - - - -

Current Ratio

4.6 4.7 5.2 1.2 1.7 2.0 2.3 2.5 2.8 1.4 1.8 2.2 2.5 2.7 3.2 3.7 10.1 2.6 2.0 1.4 1.4 1.4 1.4 3.0 3.0 3.0 3.0 1.4 1.4 1.4 1.4 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

23.2 43.7 20.3 - 129.7 47.4 33.6 - 10.3 20.0 8.6 - 229.5 37.2 56.0 - 5.8 8.9 22.6 - 15.2 8.5 54.4 - 100.3 38.5 119.0 - 160.5 65.7 70.5 - 33.7 42.1 26.3 - 9.0 8.8 8.8 - 11.4 26.9 61.4 - 76.7 15.0 - - - - - - - - - - - - -

DIO

380.8 364.4 292.8 - 878.9 588.7 944.5 - 2634.1 3115.9 1682.4 - 6658.6 286.9 145.7 - 68.3 156.8 558.0 - 259.4 57.3 192.6 - 204.5 197.2 465.0 - 188.4 157.6 354.6 - 315.2 385.3 407.8 - 226.4 277.9 233.2 - 647.9 431.9 483.6 - 91.2 127.8 - - - - - - - - - - - - -

DPO

65.2 36.1 13.6 - 22.0 15.1 31.1 - 39.8 45.6 42.6 - 574.3 77.2 71.2 - 40.9 117.4 431.7 - 257.6 56.9 197.7 - 218.0 210.2 565.0 - 382.9 320.2 748.7 - 696.8 851.7 712.9 - 277.1 340.1 236.6 - 529.2 352.8 725.4 - 263.3 368.6 - - - - - - - - - - - - -

Operating Cycle

404.0 408.1 313.1 - 1008.6 636.1 978.0 - 2644.4 3136.0 1691.0 - 6888.1 324.2 201.7 - 74.2 165.7 580.6 - 274.6 65.8 247.1 - 304.8 235.7 584.0 - 349.0 223.3 425.1 - 348.9 427.4 434.1 - 235.4 286.7 242.0 - 659.3 458.8 545.0 - 167.9 142.7 - - - - - - - - - - - - -

Cash Conversion Cycle

338.8 371.9 299.5 - 986.6 621.0 947.0 - 2604.6 3090.3 1648.5 - 6313.8 247.0 130.5 - 33.3 48.3 148.9 - 17.0 8.9 49.4 - 86.8 25.5 18.9 - -33.9 -96.9 -323.5 - -347.9 -424.3 -278.8 - -41.7 -53.4 5.4 - 130.0 106.0 -180.5 - -95.4 -225.9 - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company NanoVibronix, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 3.79 -1.81 % $ 131 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
$ 304.82 -1.07 % $ 8.6 B usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 45.27 0.3 % $ 6.74 K usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 127.9 1.93 % $ 223 B usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 91.8 -0.83 % $ 135 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.31 14.86 % $ 123 M franceFrance
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 9.62 -2.43 % $ 691 M israelIsrael
InMode Ltd. InMode Ltd.
INMD
$ 14.38 -0.9 % $ 1.14 B israelIsrael
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.96 4.69 % $ 15.5 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 96.98 0.77 % $ 1.23 B usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Align Technology Align Technology
ALGN
$ 163.71 -1.04 % $ 12.3 B usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 1.06 - $ 109 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 12.68 -0.24 % $ 343 M usaUSA
FONAR Corporation FONAR Corporation
FONR
$ 14.75 - $ 96.7 M usaUSA
AxoGen AxoGen
AXGN
$ 29.81 -1.91 % $ 1.32 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 40.03 -1.95 % $ 1.23 B usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 17.72 0.68 % $ 409 M usaUSA
Globus Medical Globus Medical
GMED
$ 86.19 -0.58 % $ 11.7 B usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 13.57 1.12 % $ 1.05 B usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 62.94 0.3 % $ 3.41 B britainBritain
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 19.86 -0.5 % $ 2.84 B usaUSA
LENSAR LENSAR
LNSR
$ 11.61 0.83 % $ 134 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 3.18 -6.49 % $ 4.96 M usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 71.95 -0.77 % $ 2.03 B costa-ricaCosta-rica